



Theraclion announces the start of clinical trials for accelerated procedure

Malakoff – July 15th, 2015 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that it has initiated a clinical trial intended to validate the performance of its new Echopulse® procedure. The proprietary technology enables significantly faster treatment delivery.

The trial was launched on June 18th and nine patients have been enrolled to date. Both thyroid nodules and breast fibroadenoma have been treated and as expected, workflow has been accelerated three-fold. *“These first treatments with the new procedure have been very promising as they were not only faster but were also a much more pleasant experience for both the patient and the physician,”* said Professor Roussanka Kovatcheva of the University Hospital of Endocrinology of Sofia, Bulgaria.

“The start of this new trial demonstrates Theraclion’s commitment to developing breakthrough treatment solutions. It is also based upon the company’s strong intellectual property,” added Sylvain Yon, deputy CEO and VP for R&D of Theraclion.

“Treatment acceleration has been a major angle of our product development strategy. In-time delivery of the announced milestones is a firm commitment to our customers and shareholders. We aim to develop HIFU (high intensity focused ultrasound) thermal ablation systems that perform at a level that is unmatched in the industry. This technology will significantly increase our physician adoption rate around the world,” said David Caumartin, CEO of Theraclion.

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 25 people, 52 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.

Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402



Contacts:

Theraclion

David Caumartin

CEO

Tel.: +33 (0)1 55 48 90 70

david.caumartin@theraclion.com

NewCap

Financial Communications & Investors relations

Emmanuel Huynh / Valentine Brouchet

Tel.: +33 (0)1 44 71 94 94

theraclion@newcap.fr

Kalima

Press Relations

Estelle Reine-Adélaïde/ Florence Calba

Tel. : + 33 (0)1 44 90 82 54

era@kalima-rp.fr